A surge in anti-dsDNA titer predicts a severe lupus flare within six months

Lupus

Volumn 23, Issue 3, 2014, Pages 293-298

  Pan, N ^a   Amigues, I ^b   Lyman, S ^a   Duculan, R ^a   Aziz, F ^c   Crow, M K ^a   Kirou, K A ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Anti DNA antibodies; nephritis; systemic lupus erythematosus

Indexed keywords

ANTI-DNA ANTIBODIES; NEPHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ACADEMIC MEDICAL CENTERS; ADULT; ANTIBODIES, ANTINUCLEAR; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DNA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 84894085865     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313515763     Document Type: Article

References (13)

1. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 1526-1533
2. Hahn BH. Antibodies to DNA. N Engl J Med. 1998 ; 338: 1359-1368
3. Kavanaugh AF, Solomon DH. Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti-DNA antibody tests. Arthritis Rheum. 2002 ; 47: 546-555
4. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis. 1986 ; 45: 359-366
5. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990 ; 33: 634-643
6. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet. 1995 ; 345: 1595-1599
7. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006 ; 54: 3623-3632
8. Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991 ; 34: 937-944
9. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 2001 ; 44: 2342-2349
10. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum. 1996 ; 39: 370-378
11. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med. 2005 ; 142 (12 Pt 1). 953-962
12. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005 ; 44: 902-906
13. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005 ; 52: 1129-1137